← Evidence library

BIB_158

NCT06112314 PRISM-MEL-301 — IMC-F106C (PRAME-targeted bispecific TCE) vs nivolumab regimens in 1L advanced melanoma. Phase III. Immunocore Ltd. 8 UK sites incl. Beatson Glasgow. [Tasks: 16, 17, 18] Tier: 1 (RCT) Grade: A (in progress) Retrieved: 2026-05-07

Evidence grade

A

Tier

1 (RCT)

Cited by tasks

16, 17, 18

Identifiers

—

Full extracted findings & patient-implication analysis: bibliography/BIB_158/findings.md (research corpus). This page is a short context summary — not individualised medical advice.